Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mPCX12
- Development stage
- Preclinical
- Lead developer
- Assertio
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
mPCX12 is an encapsulated formulation of mouse interleukin-12 (IL-12) designed for sustained, localized delivery within the tumor microenvironment. Developed by Spectrum Pharmaceuticals, it utilizes a controlled-release platform to facilitate immune activation while minimizing systemic toxicity. In preclinical models of glioblastoma, intratumoral administration of mPCX12 has been shown to increase local levels of IL-12 and interferon-gamma (IFNγ), leading to enhanced cytotoxic T-cell infiltration and prolonged survival. The human version of this candidate is referred to as hPCX12.
- Other names
- encapsulated mouse IL-12
02
Targets
IL12 (Interleukin-12)
Beyond the preview
Go deeper on mPCX12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mPCX12.